Advertisement

Search Results

Advertisement



Your search for 3 matches 16011 pages

Showing 15051 - 15100


gynecologic cancers
gynecologic cancers

Combining Ixabepilone and Bevacizumab Appears Safe and Effective in Recurrent Uterine and Ovarian Cancers

In patients with recurrent/persistent uterine or ovarian/primary peritoneal/fallopian tube cancers, ixabepilone (Ixempra), especially with the addition of biweekly bevacizumab (Avastin), appears to be safe and effective, according to a study by Roque et al in Gynecologic Oncology. Further...

palliative care
prostate cancer

ASCO 2015: Adding Chemotherapy to Initial Therapy Improves Survival in Patients With Advanced, Hormone-Naive Prostate Cancer

The UK-led STAMPEDE trial found that adding docetaxel chemotherapy to standard hormone therapy markedly improved survival for men with newly diagnosed advanced prostate cancer not previously treated with hormone therapy (hormone-naive). Men who received docetaxel plus standard therapy lived on...

skin cancer
issues in oncology

ASCO 2015: Oral Vitamin Reduces Risk of Common Nonmelanoma Skin Cancers in High-Risk Patients

The Australian ONTRAC trial showed that a form of vitamin B3 called nicotinamide significantly reduced the rates of new skin cancers in people at high risk of the disease. Taken as a twice-daily pill, nicotinamide reduced the incidence of new nonmelanoma skin cancers by 23%. These findings were...

lymphoma

No Significant Difference in Outcome for ABVD Plus Radiotherapy vs Stanford V in Stage I or II Bulky Mediastinal Hodgkin Lymphoma

As reported in the Journal of Clinical Oncology by Advani et al, a subset analysis of the phase III North American Intergroup E2496 trial showed no significant difference in failure-free or overall survival between ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) plus radiotherapy vs the...

solid tumors

Nilotinib Inferior to Imatinib in First-Line Treatment of Unresectable or Metastatic GIST

In the phase III ENESTg1 trial reported in The Lancet Oncology, Blay et al found that nilotinib (Tasigna) was associated with poorer progression-free survival vs imatinib (Gleevec) as first-line treatment in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). Trial...

colorectal cancer

Maintenance Capecitabine-Bevacizumab Prolongs Time to Second Progression in Metastatic Colorectal Cancer in Dutch Trial

In the phase III CAIRO3 trial reported in The Lancet, Simkens et al of the Dutch Colorectal Cancer Group found that maintenance capecitabine-bevacizumab (Avastin) prolonged the time to second progression vs observation in patients with metastatic colorectal cancer. In this open-label trial, 558...

lung cancer

Immune Checkpoint Inhibitor Nivolumab Active in Heavily Pretreated Advanced NSCLC

In a phase I cohort expansion trial reported in the Journal of Clinical Oncology, Gettinger et al found that monotherapy with the anti–programmed cell death protein 1 (PD-1) checkpoint inhibitor antibody nivolumab (Opdivo) produced durable responses and promising survival rates in patients...

lymphoma

UK Trial of PET-Directed Therapy Suggests That No Radiotherapy May Be an Option in PET-Negative Early-Stage Hodgkin Lymphoma

In a UK phase III RAPID trial reported in The New England Journal of Medicine, Radford et al compared no further treatment vs involved-field radiotherapy in patients with early-stage Hodgkin lymphoma who had negative positron emission tomography (PET) findings after 3 cycles of doxorubicin,...

skin cancer

Anti–PD-1 Antibody Pembrolizumab Improves Progression-Free and Overall Survival vs Ipilimumab in Advanced Melanoma

In the phase III KEYNOTE-006 trial reported in The New England Journal of Medicine, Robert et al found that the anti–PD-1 antibody pembrolizumab (Keytruda) increased progression-free and overall survival compared with ipilimumab in patients with advanced melanoma. Study Details In this...

palliative care
issues in oncology
palliative care

Surgical Interventions for Terminal Cancer Patients Remain Prevalent

The number of surgeries performed on terminally ill cancer patients has not dropped in recent years, despite more attention to the importance of less invasive care for these patients to relieve symptoms and improve quality of life. But new research from the University of California, Davis, also...

lymphoma
survivorship

Increased Lifetime Risk of Cardiovascular Disease for Patients Treated for Hodgkin Lymphoma as Adolescents or Adults

Survivors of Hodgkin lymphoma treated as adolescents or adults are at increased risk of cardiovascular disease throughout their lives, according to results of a retrospective cohort study of 2,524 Dutch patients followed for a median of 20 years. “Treating physicians and patients should be...

lung cancer

EGFR Inhibitor Rociletinib Active in EGFR T790M Mutation–Positive NSCLC Previously Treated With EGFR Inhibitors

In a phase I/II study reported in The New England Journal of Medicine, Sequist et al found that rociletinib—an EGFR inhibitor active in the presence and absence of the EGFR T790M mutation known to mediate resistance to available EGFR inhibitors—produced a high response rate in patients...

breast cancer

Nipple-Sparing Mastectomy as Safe as More Radical Procedures for Appropriate Patients

Mastectomies that preserve the nipple and an envelope of breast skin are as safe as more radical breast cancer operations for qualifying patient populations, according to one of the largest meta-analyses of studies involving women treated with this increasingly popular approach. Speaking at the...

breast cancer
issues in oncology

Overnight Fasting May Reduce Breast Cancer Risk in Women

A decrease in the amount of time spent eating and an increase in overnight fasting reduces glucose levels and may reduce the risk of breast cancer among women. Researchers at the University of California, San Diego School of Medicine reported these findings in Cancer Epidemiology, Biomarkers &...

Safety of Autologous Stem Cell Transplantation Without Hematopoietic Support in Jehovah’s Witnesses With Hematologic Malignancies

In a single-center study reported in the Journal of Clinical Oncology, Ford et al found that autologous stem cell transplantation can be safely performed without hematopoietic support in Jehovah’s Witnesses with hematologic malignancies. Jehovah’s Witnesses traditionally refuse...

gynecologic cancers
sarcoma

American College of Physicians Releases Best Practice Advice for Cervical Cancer Screening in Average-Risk Women

The American College of Physicians (ACP) released its clinical advice for cervical cancer screening in asymptomatic, average-risk women 21 years or older. Women at average risk are defined as those with no history of a precancerous lesion (cervical intraepithelial neoplasia grade 2 or a more severe ...

skin cancer

Addition of Nivolumab to Ipilimumab Improves Response Rate and Progression-Free Survival in Previously Untreated Advanced Melanoma

In a phase II study reported in The New England Journal of Medicine, Postow et al found that dual checkpoint inhibitor therapy with the anti–CTLA-4 antibody ipilimumab (Yervoy) and the anti–PD-1 monoclonal antibody nivolumab (Opdivo) produced greater response rates and prolonged...

skin cancer

FDA Accepts Supplemental Biologics License Application for Nivolumab in Patients With Previously Untreated Advanced Melanoma

The U.S. Food and Drug Administration (FDA) has accepted for filing and review Bristol-Myers Squibb’s supplemental Biologics License Application (sBLA) for nivolumab (Opdivo) for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted...

leukemia

Subgroup of Elderly Patients With Acute Myeloid Leukemia May Benefit From Initial Intensive Induction Chemotherapy

Initial intensive induction chemotherapy may be of benefit in a subgroup of newly diagnosed elderly patients with acute myeloid leukemia (AML), according to a study by Ross et al in Oncology Research. However, relapse rates remained high. Elderly patients with AML generally experience worse...

hepatobiliary cancer

Conditional Survival Estimates After Resection for Intrahepatic Cholangiocarcinoma

In a study reported in JAMA Surgery, Spolverato et al derived 3-year conditional survival estimates for patients in a multi-institutional database who underwent liver resection for intrahepatic cholangiocarcinoma. Among all patients, actuarial overall survival was 16% at 8 years, whereas 3-year...

gynecologic cancers
gynecologic cancers

Phase II Study Shows Addition of Pazopanib to Paclitaxel Improves Progression-Free Survival in Platinum-Resistant/Refractory Advanced Ovarian Cancer

In an Italian randomized phase II trial reported in The Lancet Oncology, Pignata et al found that the addition of the antiangiogenic multikinase inhibitor pazopanib (Votrient) to weekly paclitaxel significantly improved progression-free survival in patients with platinum-resistant/refractory...

leukemia

Addition of Ofatumumab to Chlorambucil Increases Progression-Free Survival in Previously Untreated CLL Patients Who Are Not Candidates for Fludarabine

In the phase III COMPLEMENT 1 trial reported in The Lancet, Hillmen et al found that the addition of the anti-CD20 antibody ofatumumab (Arzerra) to chlorambucil (Leukeran) increased progression-free survival among patients with chronic lymphocytic leukemia (CLL) who were not considered candidates...

prostate cancer

No Improvement in Undetectable PSA Rate With Cixutumumab Plus Androgen-Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer

In a randomized phase II trial (SWOG S0925) reported in the Journal of Clinical Oncology, Yu et al found that the addition of cixutumumab to androgen-deprivation therapy did not significantly increase the rate of undetectable prostate-specific antigen (PSA) in patients with newly diagnosed...

colorectal cancer

Addition of Ramucirumab to Second-Line FOLFIRI Improves Overall Survival in Metastatic Colorectal Cancer

In the phase III RAISE trial reported in The Lancet Oncology, Tabernero et al found that the addition of the antiangiogenic anti-VEGFR2 antibody ramucirumab (Cyramza) to second-line FOLFIRI (leucovorin, fluorouracil, irinotecan) improved overall survival in patients with metastatic colorectal...

breast cancer

Eligible for Breast-Conserving Therapy, Many Still Choose Mastectomy

No approved targeted therapies exist to treat triple-negative breast cancer, but new chemotherapeutic treatment strategies are helping shrink tumors so that less breast tissue needs to be removed during surgery. New research led by Brigham and Women's Hospital finds that breast-conserving therapy...

head and neck cancer

Afatinib Improves Progression-Free Survival vs Methotrexate in Platinum-Treated Recurrent or Metastatic Head and Neck Cancer

In the phase III LUX-Head & Neck 1 trial reported in The Lancet Oncology, Machiels et al found that afatinib (Gilotrif) improved progression-free survival vs methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing after first-line platinum...

breast cancer
gynecologic cancers
issues in oncology

AACR 2015: Olaparib and Investigational PI3K Inhibitor BKM120 Combination Active Against Ovarian and Breast Cancer Subtypes

Combination treatment with the poly ADP-ribose polymerase (PARP) inhibitor olaparib (Lynparza) and the investigational phosphatidylinositol-3-kinase (PI3K) inhibitor BKM120 was safe and yielded evidence of clinical benefit for women with triple-negative breast cancer and for those with high-grade...

palliative care
skin cancer

AACR 2015: Combining Two Investigational Immunotherapy Drugs Safe, With Early Signs of Effectiveness

Combining the immunostimulatory anti-CD40 monoclonal antibody CP-870,893 with the immune checkpoint inhibitor tremelimumab was found to be safe, with clinical evidence of response in patients with advanced melanoma, according to phase I clinical trial data presented at the AACR Annual Meeting 2015, ...

breast cancer

AACR 2015: Investigational PD-L1–Targeted Immunotherapy Safe for Patients With Triple-Negative Breast Cancer, Effective in Some

The investigational immunotherapy MPDL3280A was safe, tolerable, and showed early signs of durable clinical activity in patients with metastatic triple-negative breast cancer, according to data from a first-in-human phase I clinical trial presented at the AACR Annual Meeting 2015, held April 18 to...

lymphoma
survivorship

Excessive All-Cause and Second Primary Malignancy-Related Mortality and Frequent Late Morbidity in Hodgkin Lymphoma Patients Treated During Adulthood

In a single-institution study reported in the Journal of the National Cancer Institute, Matasar et al found that Hodgkin lymphoma patients treated during adulthood were at increased risk of all-cause and second primary malignancy mortality compared with SEER (Surveillance, Epidemiology, and...

issues in oncology
lung cancer

AACR 2015: Pembrolizumab Shows Promise in Non–Small Cell Lung Cancer

The immunotherapy pembrolizumab (Keytruda) was found to be safe and yielded durable responses in patients with advanced, non–small cell lung cancer (NSCLC). Those with high levels of the protein PD-L1 in their tumors had better clinical outcomes, according to phase I KEYNOTE-001 clinical...

skin cancer

AACR 2015: Pembrolizumab Is Better Than Ipilimumab for Advanced Melanoma in Phase III Trial

In the first randomized trial to compare two U.S. Food and Drug Administration–approved immune checkpoint inhibitors as first-line therapy for patients with advanced melanoma, pembrolizumab (Keytruda) yielded significantly better treatment outcomes than ipilimumab (Yervoy) for all endpoints...

hematologic malignancies
leukemia

AACR 2015: New T Cell–Based Immunotherapy Shows Promise for Lethal Stem Cell Transplant Complication

More than 60% of patients with Epstein-Barr virus–associated lymphoproliferative disorder (EBV-LPD) that was nonresponsive to standard rituximab (Rituxan) treatment responded to a new type of immunotherapy called Epstein-Barr virus–specific cytotoxic T-lymphocyte (EBV-CTL) therapy....

breast cancer

Glembatumumab Vedotin Appears Active in Heavily Treated Advanced Glycoprotein NMB–Overexpressing Breast Cancer and Triple-Negative Disease

In the randomized phase II EMERGE study reported in the Journal of Clinical Oncology, Yardley et al found that the anti–glycoprotein NMB (gpNMB) antibody-drug conjugate glembatumumab vedotin may improve response rate over alternative chemotherapy in patients with advanced refractory breast...

colorectal cancer
prostate cancer
survivorship
issues in oncology

Physical Activity Helps Cancer Survivors Fend Off Side Effects

Three or more hours of walking per week can boost the vitality and health of prostate cancer survivors. Men and women who have survived colorectal cancer and are regular walkers also reported lower sensations of burning, numbness, tingling, or loss of reflexes that many often experience after...

hematologic malignancies

Ibrutinib Is Highly Active in Previously Treated Waldenström’s Macroglobulinemia

In a study reported in The New England Journal of Medicine, Treon et al found that ibrutinib (Imbruvica) was highly active and produced durable responses in patients with previously treated Waldenström’s macroglobulinemia. Response rates were highest in patients with MYD88 mutation and...

colorectal cancer

Similar Outcomes With Laparoscopic vs Open Resection in Rectal Cancer

In the COLOR II study reported in The New England Journal of Medicine, Bonjer et al found similar rates of locoregional recurrence and disease-free and overall survival with laparoscopic vs open resection of rectal cancer. Study Details In the trial, 1,044 patients from 30 sites in 8 countries in ...

solid tumors

No Survival Benefit of Vorinostat in Progressive Advanced Malignant Pleural Mesothelioma

In the phase III VANTAGE-014 study reported in The Lancet Oncology, Krug et al found that treatment with the histone deacetylase inhibitor vorinostat (Zolinza) did not improve overall survival vs placebo in patients with malignant pleural mesothelioma who had progressed on previous chemotherapy....

leukemia

Patients With Relapsed or Refractory CLL Who Discontinue Ibrutinib Early Have Poor Outcomes

Most patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who discontinued ibrutinib (Imbruvica) early “were difficult to treat and had poor outcomes,” according to a study of patients enrolled in four different clinical trials of ibrutinib, with or without rituximab...

issues in oncology
solid tumors

Study Finds Link Between Muscle-Building Supplements and Testicular Cancer

Men who reported taking muscle-building supplements, such as pills and powders with creatine or androstenedione, reported a significantly higher likelihood of having developed testicular cancer than men who did not use such supplements, according to a study by Li et al in the British Journal of...

breast cancer
issues in oncology

Platinum Monotherapy Particularly Active in BRCA1/2-Mutant Metastatic Triple-Negative Breast Cancer

In the phase II TBCRC009 trial reported in the Journal of Clinical Oncology, Isakoff et al found that platinum monotherapy was active in treatment of metastatic triple-negative breast cancer, particularly in cases with BRCA1/2 mutation, and that an assay of genomic instability characteristic of...

gynecologic cancers
head and neck cancer
issues in oncology
cost of care

Increasing Number of Boys Vaccinated Against HPV Could Protect More People at the Same Price

Public health programs that devote a portion of their funding to encourage more boys to be vaccinated against human papillomavirus (HPV)—rather than merely attempting to raise coverage among girls—may ultimately protect more people for the same price, a study from Duke University...

gynecologic cancers

Complete Regression of Metastatic Cervical Cancer Is Observed After Treatment With HPV-Targeted Tumor-Infiltrating T Cells

As reported in the Journal of Clinical Oncology, Stevanovíc et al observed complete regression of metastatic cervical tumors in two patients following a single infusion of human papillomavirus (HPV)-targeted tumor-infiltrating T cells. In the protocol, nine patients with metastatic cervical ...

kidney cancer
kidney cancer

Durable Responses With Nivolumab in Previously Treated Advanced Renal Cell Carcinoma

In a phase I cohort-expansion study reported in the Journal of Clinical Oncology, McDermott et al found that nivolumab (Opdivo) produced durable responses in patients with previously treated advanced renal cell carcinoma. Responses continued after nivolumab discontinuation in some patients. Study...

head and neck cancer

Stereotactic Body Radiotherapy Plus Cetuximab Appears Safe, Effective in Previously Irradiated Recurrent Head and Neck Squamous Cell Carcinoma

In patients with previously irradiated recurrent squamous cell carcinoma of the head and neck, the combination of stereotactic body radiation therapy plus cetuximab (Erbitux) appears to be safe and effective, according to a study by Vargo et al in the International Journal of Radiation Oncology...

breast cancer

Worse Outcomes With Lapatinib vs Trastuzumab Plus Taxane in Advanced HER2-Positive Breast Cancer

In the phase III National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) MA.31 trial, first-line treatment with lapatinib (Tykerb) vs trastuzumab (Herceptin) combined with a taxane was associated with poorer progression-free survival and greater toxicity in patients with advanced...

skin cancer

One in Five Medicare Patients With Melanoma Experience Surgical Delays

A large retrospective cohort study of more than 32,000 Medicare beneficiaries diagnosed with melanoma has found that one in five patients experience a delay of surgery that is longer than 1.5 months. Those patients undergoing biopsy and surgery by dermatologists had the lowest risk for delay, which ...

skin cancer

Adjuvant Ipilimumab Increases Recurrence-Free Survival vs Placebo After Complete Resection of High-Risk Stage III Melanoma

In the phase III EORTC 18071 trial reported in The Lancet Oncology, Eggermont et al found that adjuvant ipilimumab (Yervoy) significantly improved recurrence-free survival vs placebo in patients with completely resected stage III melanoma at high risk of disease recurrence. Ipilimumab was...

gynecologic cancers

FDA Grants Breakthrough Therapy Designation to Rucaparib in Advanced Ovarian Cancer With BRCA Mutations

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Clovis Oncology’s investigational agent rucaparib as monotherapy treatment of advanced ovarian cancer in patients who have received at least two lines of prior platinum-containing therapy, with...

sarcoma

Persistence of HER2-Specific CAR T Cells in HER2‑Positive Sarcoma

In a phase I/II study reported in Journal of Clinical Oncology, Ahmed et al found that infusion of T cells expressing HER2-specific chimeric antigen receptor (CAR) with a CD28.ζ signaling domain (HER2-CAR T cells) could produce persistent CAR T cell levels for ≥ 6 weeks in patients with...

Advertisement

Advertisement




Advertisement